Lidocaine/Oxybutynin controlled release - Trigone Pharma
Alternative Names: Lidocaine/Oxybutynin sustained release - Trigone Pharma; TRG-100Latest Information Update: 19 Aug 2021
At a glance
- Originator Trigone Pharma
- Class Antispasmodics; Local anaesthetics; Urologics
- Mechanism of Action Cholinergic receptor antagonists; Muscarinic receptor antagonists; Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Interstitial cystitis
Most Recent Events
- 13 Aug 2021 Phase-II clinical trials in Interstitial cystitis (Treatment-experineced) (Intravesicular)
- 22 Jul 2021 Preclinical trials in Interstitial cystitis in Israel (Intravesicular)
- 22 Jul 2021 Adverse events and pharmacokinetics data from a preclinical study in Interstitial cystitis released by Trigone Pharma